Registration for a live webinar on 'Precision medicine treatment for anticancer drug resistance' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Before we begin…
- Aging doubles your risk of chronic diseases
- The pituitary gland and growth hormone
- Ames dwarf mice
- Various mutations affecting GH signaling
- Can longevity be reversed?
- Results from GH treatment of mice
- The effect of GH therapy in early life
- Investigating the mechanism of action
- Next steps
- Some contributing pathways
- GH can cause DNA damage
- Impact of GH in cell senescence
- Further questions
- Trade-offs between growth and aging
- Trade-offs between growth and longevity
- Other questions we must ask
- Do the results apply to normal mice?
- Small dogs outlive big dogs
- Do the results apply to humans?
- Height is inversely associated with longevity
- Leiden longevity study
- Humans with isolated GH deficiency (IGHD)
- Go team!
- Increased healthspan in IGHD individuals
- Human phenotype compared to mouse phenotype
- Laron dwarfism
- GH resistance protects from diabetes and cancer
- Findings in humans vs. findings in mice
- Fast vs. slow life history strategies
- What is 'pace-of-life'?
- Allocating resources
- What happens when there's too much GH?
- Conditions arising from excess GH
- Acromegaly
- Evolutionary trade-offs between growth, reproduction, aging and longevity
- Acknowledgements
Topics Covered
- Growth hormone
- Aging and chronic disease
- Ames dwarf mice models
- Trade-offs between growth and aging
- Longevity studies in humans
- Isolated GH deficiency
- Pace-of-life
- Healthspan
- Lifespan
Links
Categories:
Therapeutic Areas:
Talk Citation
Bartke, A. (2023, April 30). Role of growth hormone in aging [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 22, 2024, from https://doi.org/10.69645/ESVR4852.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Andrzej Bartke has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
A selection of talks on Cardiovascular & Metabolic
Transcript
Please wait while the transcript is being prepared...
0:00
Our topic today is the regulation of
mammalian aging by growth hormone.
0:08
Before going into this topic,
I thought we can spend a
few moments thinking about
what is the reason that we're
interested in studying aging,
and why we feel that this
research may be important.
0:24
What is shown in this image is
the incidence of a variety
of chronic diseases:
heart conditions, diabetes,
dementia, and so forth,
and also all-cause mortality.
What is obvious is that the
incidence of all of this,
the risk for all those diseases
increases very much with age.
In many cases,
aging is, in fact,
the most important risk factor
with nothing really
coming close.
Please note that these data are
plotted on the
logarithmic scale.
In other words, if this
was a linear scale,
the lines would have
been almost vertical.
It's a very dramatic increase
in the risk factor with age.
Now, most people
working in the biology of
aging including our group,
feel this data along
with other evidence
implies that if we could
reduce the rate of aging
if we could inhibit their
biological process of aging,
we could produce an
important reduction
in the risk of all
these diseases.
That, in fact, we could
postpone them or make
them less common.
There is considerable
evidence from work
in experimental animals
showing that this goal,
even though it may appear to be
very difficult, is
probably realistic.
That, in fact, in
situations where we
can slow the aging process
and extend longevity,
we also postpone the onset
of aging-related diseases,
and we can reduce
their incidence.
Since we are interested in,